Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy.

British journal of cancer - 23 Apr 2007

Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais M P, Bastit L, Killian A, Sesboüé R, Tuech J J, Queuniet A M, Paillot B, Sabourin J C, Michot F, Michel P, Frebourg T

Abstract excerpt

The predictive value of KRAS mutation in metastatic colorectal cancer (MCRC) patients treated with cetuximab plus chemotherapy has recently been suggested. In our study, 59 patients with a chemotherapy-refractory MCRC treated with cetuximab plus chemotherapy were included and clinical response was evaluated according to response evaluation criteria in solid tumours (RECIST). Tumours were screened for KRAS...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Cetuximab

Share to Colorectal Neoplasms

Share to ErbB Receptors

Share to Genes, ras

Share to Neoplasm Metastasis

Source

Open in PubMed Open full text

Identifiers

PMID: 17375050
DOI: 10.1038/sj.bjc.6603685
PMCID: PMC2360149

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy.PMID 17375050Read ↗

Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: a meta-analysis of 22 studies.Semantic proximity Read ↗

Comparison of methodologies for KRAS mutation detection in metastatic colorectal cancer.Semantic proximity Read ↗

Genetic analysis of KRAS mutation status in metastatic colorectal cancer patients.Semantic proximity Read ↗

KRAS mutations and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal carcinoma: an open issue.Semantic proximity Read ↗

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Semantic proximity Read ↗

Concordant analysis of KRAS status in primary colon carcinoma and matched metastasis.Semantic proximity Read ↗

KRAS status and resistance to epidermal growth factor receptor tyrosine-kinase inhibitor treatment in patients with metastatic colorectal cancer: a meta-analysis.Semantic proximity Read ↗

Impact of KRAS mutation on outcome of patients with metastatic colorectal cancer.Semantic proximity Read ↗

Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer.Semantic proximity Read ↗

KRAS mutation testing in metastatic colorectal cancer.Semantic proximity Read ↗

The treatment of colorectal carcinoma with monoclonal antibodies: the importance of KRAS mutation analysis and EGFR status.Semantic proximity Read ↗

The role of KRAS mutations in predicting the efficacy of cetuximab-plus-irinotecan therapy in irinotecan-refractory Korean metastatic colorectal cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.